Reuters logo
BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization
August 21, 2017 / 11:21 AM / 2 months ago

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

Aug 21 (Reuters) - Bioline Rx Ltd:

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization

* Bioline RX Ltd - ‍initiation of study expected by end of 2017​

* Bioline RX Ltd- ‍trial, named genesis, is expected to commence by end of 2017, following receipt of regulatory approval​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below